A significant disconnect exists between the FDA leadership's public statements promoting flexibility and the stringent, delay-prone reality faced by companies. For areas like gene therapy, firms report feeling the "rug was pulled out," suggesting investors should be skeptical of the agency's accommodating PR.

The FDA publicly champions rare disease drug development, but its actions—frequent and inconsistent rejections—tell a different story. This disconnect between rhetoric and reality creates significant uncertainty, causing prominent investors like Rod Wong of RTW Investors to reduce their investments in the space.

Biotech companies are intensely reliant on the FDA for approvals, making it nearly impossible to enforce legal agreements or challenge the agency publicly, even when wronged. This "repeat relationship" means the FDA ultimately holds all the power, making any direct conflict a perilous decision for a company.

Facing a negative FDA decision, Replimune has filed a Freedom of Information Act (FOIA) request to investigate why senior FDA leadership allegedly overruled its own review team. This legalistic tactic moves beyond scientific debate into a public challenge of the agency's internal processes and transparency.

After the first FDA rejection, Replimune's chairman reveals they lacked funds to complete their confirmatory study to statistical significance. This forced them to submit a weaker "descriptive analysis" of early data for their second review—a high-risk gamble dictated by financial reality rather than an optimal regulatory strategy.

Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.

The FDA advised against a single-arm study unless data was "sufficiently compelling." Replimune argues the FDA's subsequent actions—granting priority review and not objecting to the filing—implied the data met this bar, making the final rejection based on the study design feel disingenuous and like a retrospective goalpost shift.

Recent conspiracy theories blame the WHO for suppressing cancer cures. However, the WHO has no drug approval authority in the US. The FDA is the sole regulator, making it the more logical focus for scrutiny and reform advocacy regarding healthcare innovation.

The FDA's second Complete Response Letter for Replimune's advanced melanoma drug is a disappointing signal for the industry. Despite having what appeared to be a decent risk-benefit profile, the rejection suggests the regulatory bar for approvals based on single-arm studies remains unpredictably high and a head-scratcher for observers.